The tetravalent bispecific antibody AFM13, with two binding sites for each CD30 and CD16A (FcγRIIIα), can recruit and activate CD16A+ NK cells to CD30-expressing tumor cells and can subsequently mediate tumor cell killing [140]. This evidence concerns the gene TNFRSF8 and neoplasm.